On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the March 2025 CRG meeting. Actions in this consultation include:
- FreeStyle Libre – add FSL2 plus and FSL3 plus, and remove FSL2 and FSL3
- Liraglutide for T2DM – remove Victoza brand name from formulary and replace with best value biosimilar statement
- Buserelin – remove 150 micrograms nasal spray (discontinued)
- Exagamglogene autotemcel for severe sickle cell diseases – RED
All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.
This consultation will run for six weeks and closes at 5pm on Monday 1st May 2025. To take part, visit the consultations page.